ATI 9242Alternative Names: ATI-9242
Latest Information Update: 25 Nov 2016
At a glance
- Originator ARYx Therapeutics
- Developer ARYx Therapeutics; Braeburn Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action Acetylcholine stimulants; Dopamine release stimulants; GABA modulators; NMDA receptor modulators; Serotonin-7 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Schizophrenia